Sona Nanotech Inc.

Recent News

  • Sona Nanotech Receives CE Mark Approval for its Rapid COVID-19 Antigen Test

    Halifax, Nova Scotia--(Newsfile Corp. - December 31, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company", "Sona") a developer of rapid, point-of-care diagnostic tests, has been granted CE Mark status for its rapid, COVID-19 antigen test. The CE Mark declares the conformity of the Sona test with EU regulations and allows Sona to commercialize its test throughout Europe and potentially other territories in which the CE Mark is recognized.The Company intends to begin selling its test as...

    2020-12-31 9:08 AM ET
  • Sona Nanotech Closes Unbrokered Private Placement Financing for $2.26M in Gross Proceeds

    Halifax, Nova Scotia--(Newsfile Corp. - December 16, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company", "Sona") a developer of rapid, point-of-care diagnostic tests, is pleased to announce that it has closed its non-brokered private placement that was announced on December 3, 2020 with the issuance of 2,259,200 units at $1.00 per unit.The final amount of the offering represents an increase from the Company's previously announced intention to raise up to $2,000,000 through a non-brokered private placement...

    2020-12-16 9:32 AM ET
  • Sona Nanotech Comments on Market Activity

    Halifax, Nova Scotia--(Newsfile Corp. - December 10, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company", "Sona") a developer of rapid, point-of-care diagnostic tests, at the request of Investment Industry Regulatory Organization of Canada (IIROC), confirms that it is not aware of any reason for today's increase in market activity in its shares and there has been no material change or information to report under applicable securities laws that would account for today's trading activity in its common...

    2020-12-10 1:09 PM ET
  • Sona Nanotech $2M Private Placement Financing Fully Subscribed

    Halifax, Nova Scotia--(Newsfile Corp. - December 8, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") a developer of rapid, point-of-care diagnostic tests, is pleased to announce that its previously announced non-brokered private placement for up to $2,00,000 is now fully subscribed. The Company expects to close the Financing shortly. The Company previously announced its intention to raise up to $2,000,000 through a non-brokered private placement (the "Financing") of up to 2,000,000...

    2020-12-08 9:35 AM ET
  • Sona Nanotech Arranges Private Placement Financing and Appoints EU Agent for Application for CE Mark

    Halifax, Nova Scotia--(Newsfile Corp. - December 3, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") a developer of rapid, point-of-care diagnostic tests, is pleased to announce that it plans to raise up to $2,000,000 through a non-brokered private placement (the "Financing") of up to 2,000,000 units of Sona (each, a "Unit") at $1.00 per Unit. Each Unit will consist of one common share of Sona (a "Common Share") and one-half of a Common Share purchase...

    2020-12-03 9:00 AM ET
  • Sona Nanotech Provides Corporate Update

    Halifax, Nova Scotia--(Newsfile Corp. - November 30, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company"), a developer of rapid, point-of-care diagnostic tests, received further feedback from Health Canada, subsequent to its withdrawal of its application for an Interim Order authorization ("IO") for the marketing of its rapid, COVID-19 antigen test. As part of its review, Health Canada commissioned an evaluation from the National Microbiology Laboratory (NML) whose evaluation produced discordant results to the Company's prior analytical...

    2020-11-30 8:58 AM ET
  • Sona Nanotech Withdraws Rapid COVID-19 Antigen Test Application Based on Feedback from Health Canada

    Halifax, Nova Scotia--(Newsfile Corp. - November 25, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company"), a developer of rapid, point-of-care diagnostic tests, withdrew its application for an Interim Order authorization ("IO") from Health Canada for the marketing of its rapid, COVID-19 antigen test in order to obtain more clinical data to augment its submission. The Company is committed to working with regulators to provide additional information and analysis on its test and to re-submitting its application...

    2020-11-25 1:50 PM ET
  • Sona Nanotech Appoints New Director

    Halifax, Nova Scotia--(Newsfile Corp. - November 3, 2020) - Sona Nanotech Inc. (CSE: SONA) (the "Company") is pleased to announce the appointment of Mr. J. Mark Lievonen, C.M., to the Company's Board of Directors. Mr. Lievonen is the former President of Sanofi Pasteur Limited, the Canadian vaccine division of Sanofi. Under his leadership, Sanofi Pasteur became a billion dollar enterprise in Canada, manufacturing over 50 million doses of vaccines for both domestic and international markets. Mr. Lievonen spearheaded a cancer...

    2020-11-03 8:18 AM ET